The global biomaterials market size was estimated at USD 178.0 billion in 2023 and is projected to grow at a CAGR of 15.6% from 2024 to 2030. The growing incidence of musculoskeletal and chronic skeletal medical conditions is expected to stimulate the demand for implants based on biomaterials, thereby enhancing market expansion. The increasing prevalence of chronic conditions such as osteoarthritis and degenerative diseases intensifies the demand for advanced biomaterials. Joint replacements and augmentations become essential interventions for individuals facing limited mobility and pain due to these conditions.
Metallic biomaterials address this need by offering durable and long-lasting solutions that integrate with the body, restoring functionality and enhancing the quality of life for affected individuals. Technological advancements continually refine biomaterials, tailoring them to meet specific medical requirements. Innovations focus on improving biocompatibility, corrosion resistance, and the ability to integrate seamlessly with biological systems.
This evolution enables the creation of implants that not only withstand the body's biomechanics but also promote healing & integration, reducing the risk of complications post implantation. In addition, the aging global population contributes significantly to the demand for biomaterials. As the population ages, the prevalence of chronic conditions and age-related injuries rises, amplifying the necessity for effective and durable medical interventions. Biomaterials play a pivotal role in addressing these healthcare challenges by offering solutions that align with the unique needs of an aging demographic.
Furthermore, the demand for novel biomaterials has been increasing in recent years owing to their growing application in tissue replacement & repair, such as bones, teeth, and other organs. This rising adoption can be attributed to technological developments, particularly in nanotechnology-enabled approaches for administering treatments at the molecular-length scale. In addition, advanced biomaterials offer a promising solution to the challenges faced by autologous or allograft-based treatments, such as shortage of donors, possible immune rejection, and size or modality mismatches.
Polymeric artificial constructs mimic the structural and functional properties of the extracellular matrix, which can be used for promoting cell growth. Moreover, several advanced polymeric substances are also being introduced to complement existing implant solutions and to improve their efficiency. For instance, in March 2022, Evonik expanded its offerings for 3D-printable biomaterials with the launch of its osteoconductive VESTAKEEP iC4800 3DF PEEK filament, which can improve the fusion between implants and bone. Such innovations are expected to expand the growth prospects for biomaterials market.
The market is witnessing a high degree of innovation, with advancements in bioengineering, nanotechnology, and regenerative medicine driving the development of novel materials for medical applications. This innovation is fostering the creation of bio-compatible and bio-functional materials that enhance tissue regeneration and medical device performance.
Several market players such as Medtronic plc, Evonik Industries AG, and Dentsply Sirona, are involved in merger and acquisition activities. Through M&A activity, these companies can expand their geographic reach and enter new territories.
Stringent regulatory frameworks are shaping the biomaterial market, ensuring product safety and efficacy, and driving industry compliance. Adherence to these regulations is essential for market entry and sustained growth in the biomaterial sector.
Biologically derived materials, such as plant-based polymers and tissue-engineered constructs, present potential substitutes in the biomaterial market, challenging traditional synthetic options. Continuous research into alternative sources and sustainable biomaterials is driving exploration of eco-friendly alternatives with diverse.
The market is experiencing robust regional expansion, driven by increasing healthcare investments, growing aging populations, and rising demand for advanced medical technologies in emerging economies. This expansion reflects a global shift towards adopting biomaterials for diverse medical applications, creating new opportunities for market growth.
The metallic segment held the largest revenue share of over 40.0% in 2023 due to their unique combination of mechanical properties, biocompatibility, and corrosion resistance. Metals are the most widely used biomaterials and are generally used for manufacturing load-bearing implants. For instance, metallic implants are used on a large scale during orthopedic surgeries. They consist of simple wires, screws, fracture fixation plates, and total joint prostheses (artificial joints) for hips, knees, shoulders, ankles, etc. Thus, the well-established track record of metallic biomaterials in medical applications, coupled with ongoing research to enhance their functionalities, solidifies their dominance in the market, contributing to their widespread use in various medical devices and implants.
The natural segment is expected to showcase lucrative growth during the forecast period due to its advantages in terms of biodegradability, biocompatibility, and remodeling compared to synthetic biomaterials, the product is increasingly utilized to replace or restore the structure and function of damaged organs or tissues. For instance, the biosensor, an analytical device employed to detect analytes such as biomolecules or biological elements produced by microorganisms, tissues, enzymes, organelles, and so on. Moreover, when implanted, natural biomaterials possess the capacity to facilitate cell adhesion, proliferation, and differentiation, thereby playing a crucial role in the anticipated growth of this segment in the coming years.
The orthopedic segment accounted for the largest revenue share in 2023. The growing adoption of metallic biomaterials in orthopedic applications, attributed to their high load-bearing capacity, is a key factor fueling the growth of this segment. In addition, the continuous efforts by market vendors to introduce advanced orthopedic implants are expected to drive revenue generation. For instance, in November 2019, DiFusion Inc. obtained FDA approval for its Xiphos-ZF spinal interbody device, which utilizes a unique biomaterial called Zfuze- a combination of poly-ether-ether-ketone and titanium. This innovative biomaterial has demonstrated significant reductions in cytokine markers associated with inflammation and fibrous tissue formation.
The plastic surgery segment is estimated to register the fastest CAGR over the forecast period due to the increasing demand for cosmetic procedures and the need for reconstructive surgeries after accidents or diseases. In addition, advancements in biomaterial technology have led to the development of more durable and customizable implants, further driving the market. Moreover, the growing aging population coupled with a rising obsession for youthful looks is expected to fuel the demand for plastic surgery, thereby impacting positively on the overall segment growth.
North America dominated the overall biomaterials market in 2023. This is due to the initiatives by various public and private organizations, including the National Science Foundation and the National Institute of Standards and Technology, offering expertise and support regarding the utilization of biomaterials in biomedical applications. This has led to an increased adoption of biomaterials in the region. Furthermore, favorable government policies and the concentration of numerous major market players in this area have played a significant role in contributing to the regional market share.
The U.S. accounted for the largest share of the biomaterials market in North America region in 2023. The large market share of the U.S. can be attributed to the presence of major market players involved in the manufacture and introduction of innovative solutions for reconstructive surgical procedures. In addition, homegrown companies form strategic partnerships with each other as well as foreign-established enterprises to enhance their presence in the implants market, which in turn is expected to boost market growth in the coming years.
The Europe biomaterials market is expected to grow significantly over the forecast period. The region exhibited significant growth, attributed to the investments & innovations by major players, established industrial infrastructure, and supportive government regulations. Several Germany-based organizations support and are focused on providing safer & more biocompatible biomaterials in the coming years. The increase in investments from biopharmaceutical manufacturing companies is also an important market driver.
The biomaterials market in the UK held the major share in 2023. Cardiovascular diseases affect around 7 million people in the UK and are a major cause of death and disability. Cardiovascular diseases are responsible for one in four premature deaths in the country and account for the major gap in healthy life expectancy. Biomaterials are used in the restoration and replacement of cardiovascular tissues. Thus, high prevalence of cardiovascular disorders is expected to influence the UK market’s growth.
The Germany biomaterials market held a significant revenue share in 2023. The Germany market is expected to grow in tandem with the overall Europe market, owing to the increasing need for grafting procedures and subsequent development of biomaterials by prominent market players. Presence of companies involved in the development and marketing of biomaterials used for implants in Germany is anticipated to drive the market growth in the coming years. Moreover, there has been a paradigm shift toward biomaterials used in reconstruction in the past few years. Proven safety of biomaterials and constant developments in biomaterials have contributed to the increase in the demand for biomaterials.
The market for biomaterials in France witnessed significant growth as a result of the country's aging population and rising incidence of neurological diseases. France's population is continuously increasing, and as of the beginning of 2018, the population was 67.2 million, according to the Insee National Statistics of France. It revealed a huge increase of 233,000 persons in 2017, an increase of 0.3%. According to Fondation de France, nearly 19.6% of the French population is now over the age of 65, up from 15.5% 20 years ago, and one in every five French citizens is over the age of 60. This rise in the aging population has led to incidence of several conditions, including neurodegenerative and ophthalmic diseases in the country. For instance, according to ICM (Brain & Spine Institute), in France, Parkinson's disease is the second cause of motor disability, with 8,000 new cases each year.
The Asia Pacific region is expected to grow at the fastest CAGR during the forecast period. This is due to the strategic initiatives implemented by regional participants to strengthen their position in both local and global markets. For instance, in November 2019, Mitsubishi Chemical, a Japan-based company, entered into an agreement with AdvanSource Biomaterials, a U.S.-based firm, to acquire their thermoplastic polyurethane elastomer business. This strategic acquisition is anticipated to enhance their global business presence and secure a substantial share in the international market.
The Japan biomaterials market accounted for the largest share in 2023. This is due to its advanced healthcare infrastructure, substantial research and development initiatives, and a rapidly aging population. The country has a strong emphasis on technological innovation and medical advancements, leading to significant investments in biomaterial research and application. Japan's well-established regulatory framework ensures the safety and efficacy of biomaterials, fostering their widespread adoption in medical devices and regenerative medicine.
The biomaterials market in China is fragmented with local players that collectively dominate every sub-segment. Local players control more than half of the total market, with foreign players holding the remaining, which is mainly due to lower price points and significant financial & regulatory backing from the government. Two notable foreign players in China are Weigao Group from China and Evonik Industries from Germany, whose products have leading positions in the overall market.
The Middle East & Africa region is expected to witness growth during the forecast period due to the increasing scientific awareness and adoption of biomaterial technologies for the development of medical devices in the region. Similarly, the high prevalence of chronic disease conditions such as cardiovascular disease in the Middle East region is also fueling the market. For instance, according to a study published in the American Journal of Preventive Cardiology, UAE witnesses one of the highest age-standardized death rates for cardiovascular disease. This is anticipated to lead to a high demand for cardiac health solutions such as stents, grafts, etc. which can boost the market growth.
The South Africa biomaterials market is expected to account for a small share as compared to other countries & regions in this market. The developing life sciences field and rising disease-oriented studies with untapped opportunities are few factors expected to drive the segment growth in the coming years. However, slower economic growth is anticipated to impede market growth to some extent in this country. The South African government recognizes the potential of the biomaterials industry and provides support through initiatives such as the Biomanufacturing Innovation Centre (BMIC) and the Technology Innovation Agency (TIA). This support fosters research, development, and commercialization of biomaterials.
The market players are adopting product approval to increase the reach of their products in the market and improve the availability of their products in diverse geographical areas, along with expansion as a strategy to enhance production/research activities. In addition, several market players are acquiring smaller players to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve their competencies.
In March 2023, Invibio Biomaterial Solutions launched the polyetheretherketone polymer-based Peek-Optima Am filament for manufacturing 3D-printed medical devices.
In January 2023, Zimmer Biomet Holdings, Inc. announced plans to acquire Embody, Inc. for USD 155 million at closing, potentially increasing to USD 275 million based on future milestones. The deal can strengthen Zimmer Biomet's sports medicine portfolio, focusing on soft tissue healing solutions.
In October 2023, Evonik introduced VESTAKEEP iC4612 3DF and iC4620 3DF, the world's first carbon-fiber-reinforced PEEK filaments for 3D-printed medical implants, offering strength, ductility, and adaptability. This innovation signifies Evonik's commitment to advancing patient-specific medical treatments.
Report Attribute |
Details |
Market size value in 2024 |
USD 205.11 billion |
Revenue forecast in 2030 |
USD 488.70 billion |
Growth rate |
CAGR of 15.6% from 2024 to 2030 |
Base year for estimation |
2023 |
Historical data |
2018 - 2022 |
Forecast period |
2024 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2024 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, application, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; Thailand; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
Key companies profiled |
Medtronic; Evonik Industries AG; Carpenter Technology Corporation; Berkeley Advanced Biomaterials; Invibio Ltd.; Zimmer Biomet Holdings, Inc.; BASF SE; Covalon Technologies Ltd.; Stryker; Johnson & Johnson; Dentsply Sirona; CoorsTek Inc.;Corbion; Regenity Biosciences |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global biomaterials market report based on product, application, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Metallic
Natural
Ceramics
Polymers
Application Outlook (Revenue, USD Million, 2018 - 2030)
Cardiovascular
Sensors
Stents
Guidewires
Implantable Cardiac Defibrillators
Pacemakers
Vascular Grafts
Others
Ophthalmology
Synthetic Corneas
Intraocular Lens
Contact Lens
Ocular Tissue Replacement
Others
Dental
Tissue Regeneration Materials
Dental Implants
Bone Grafts & Substitutes
Dental Membranes
Others
Orthopedic
Joint Replacement Biomaterials
Orthobiologics
Bioresorbable Tissue Fixation Products
Viscosupplementation
Spine Biomaterials
Others
Wound Healing
Fracture Healing Device
Adhesion Barrier
Skin Substitutes
Internal Tissue Sealant
Surgical Hemostats
Others
Tissue Engineering
Plastic Surgery
Facial Wrinkle Treatment
Soft Tissue Fillers
Craniofacial Surgery
Bioengineered Skins
Peripheral Nerve Repair
Acellular Dermal Matrices
Others
Neurology
Neural Stem Cell Encapsulation
Shunting Systems
Hydrogel Scaffold For CNS Repair
Cortical Neural Prosthetics
Others
Others
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Thailand
Australia
Latin America
Brazil
Mexico
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
b. The global biomaterials market size was estimated at USD 178.0 billion in 2023 and is expected to reach USD 205.11 billion in 2023.
b. The global biomaterials market is expected to grow at a compound annual growth rate of 15.6% from 2024 to 2030 to reach USD 488.70 billion by 2030.
b. The metallic product segment dominated the biomaterials market with a share of 40.0% in 2023. The wide availability of metallic and advanced materials for tissue fixation and other orthopedic applications is expected to accelerate segment revenue generation.
b. Some key players operating in the biomaterials market include Medtronic plc; Evonik Industries AG; Carpenter Technology Corporation; Berkeley Advanced Biomaterials; Invibio Ltd.; Zimmer Biomet Holdings, Inc.; BASF SE; Covalon Technologies Ltd.; Stryker; Johnson & Johnson; Dentsply Sirona; CoorsTek Inc.;Corbion; and Collagen Matrix, Inc.
b. Key factors that are driving the biomaterials market growth include rising demand as a consequence of accidental injuries & chronic conditions, advances in biomaterials technologies, and expansion in the usage scope of biomaterials.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."